Globus Medical Is Firing on All Cylinders with Its Spine Robotics Platform (and Investors Are Noticing)

A medtech analyst shares insights for one of his most frequently asked about companies.

Amanda Pedersen

October 19, 2021

2 Min Read
Globus Medical

In recent weeks, Needham & Co.'s team of medtech analysts met with a series of investors across several regions of the United States. We previously shared their insights on AtriCureHaemoneticsNuVasive, and LivaNova. Globus Medical was also among the most frequently asked about companies during those conversations, according to a report from Needham's Mike Matson, David Saxon, and Joseph Conway. More specifically, investors have honed in on the company's success in spine robotics.

The Audubon, PA-based company won FDA clearance for Excelsius3D in August. The intraoperative 3-in-1 imaging system was previously identified by MD+DI as one of the 10 most anticipated new medical devices of the year.

"[Globus Medical's] above-market revenue grwoth has been driven by implant pull-through from the ExcelsiusGPS robot, sales force expansion, and new product launches," the analysts note in the report. "We expect this to continue into 2022, which should be augmented by the launch of its Excelsius3D imaging system. Recent checks continue to suggest GMED's ExcelsiusGPS platform has advantages over competitive robotics platforms."

Globus says Excelsius3D consolidates 360-degree cone-beam CT, fluoroscopy, and high-resolution digital radiography into one unified solution, eliminating the need for multiple imaging systems during one procedure. The company touts the system's precise motion, omnidirectional wheels, and intelligent maneuverability. Excelsius3D functions as a standalone imaging unit, or as an extension to the Excelsius ecosystem, Globus said.

“Excelsius3D underwent rigorous performance testing of various capabilities to support this 510(k) clearance, as it is our first imaging system 510(k) to be filed with the FDA’s Office of In Vitro Diagnostics and Radiological Health,” said Kelly Baker, PhD, senior vice president of regulatory and clinical affairs at Globus. “We are excited to expand into a new product space with the FDA and help bring this truly innovative system to market.”

The company noted that it is ramping up production and preparing for commercial release of Excelsius3D in the fourth quarter. The system is designed for 2D fluoroscopy, 2D digital radiography, and 3D imaging of adult and pediatric patients. It is indicated for use where a physician benefits from 2D and 3D information on anatomic structures and high contrast objects with high x-ray attenuation such as bony anatomy and metallic objects.

Globus launches ExcelsiusGPS Cranial Solutions

Globus also recently announced the first surgery performed with its ExcelsiusGPS Cranial Solutions for robot-assisted navigated deep brain stimulation (DBS). Cranial Solutions is the latest evolution of the ExcelsiusGPS platform, transforming it to a 2-in-1 application system, and is now commercially available in the United States.

ExcelsiusGPS Cranial Solutions combines streamlined MRI preoperative planning with fully integrated robotic trajectory alignment for a broad spectrum of cranial stereotactic procedures, Globus said. The platform is designed to adapt to each surgeons’ workflow and preferred instruments.

About the Author(s)

Amanda Pedersen

Amanda Pedersen is a veteran journalist and award-winning columnist with a passion for helping medical device professionals connect the dots between the medtech news of the day and the bigger picture. She has been covering the medtech industry since 2006.

Sign up for the QMED & MD+DI Daily newsletter.

You May Also Like